Topical pimecrolimus versus betamethasone for oral lichen planus: a randomized clinical trial
ConclusionPimecrolimus showed earlier clinical response and less recurrence rate compared with standard topical corticosteroid in symptomatic OLP lesions, and both treatment reduced CD133-positive CSC population.Clinical relevanceThe study proved the benefits of topical pimecrolimus in early management of painful lesions of OLP and its ability to inhibit CSCs, suggesting a possible role in reducing risk of malignant transformation.
Source: Clinical Oral Investigations - Category: Dentistry Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Corticosteroid Therapy | Dentistry | Elidel | Head and Neck Cancer | Lichen Planus | Oral Cancer | Pain | Pain Management | Study